CoChat

Tau fibrils induce glial inflammation and neuropathology via TLR2 in Alzheimer’s disease–related mouse models

Open access
Dutta, Debashis, Jana, Malabendu, Paidi, Ramesh Kumar, Majumder, Moumita, Raha, Sumita, Dasarathy, Sridevi, Pahan, Kalipada · 2023 · Journal of Clinical Investigation

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Glial activation and inflammation coincide with neurofibrillary tangle (NFT) formation in neurons. However, the mechanism behind the interaction between tau fibrils and glia is poorly understood. Here, we found that tau preformed fibrils (PFFs) caused induction of inflammation in microglia by specifically activating the TLR2/MyD88, but not the TLR4/MyD88, pathway. Accordingly, the WT TLR2-interacting domain of MyD88 (wtTIDM) peptide inhibited tau PFF-induced activation of the TLR2/MyD88/NF-κB pathway, resulting in reduced inflammation. Nasal administration of wtTIDM in P301S tau-expressing PS19 mice was found to inhibit gliosis and inflammatory markers, as well as to reduce pathogenic tau in the hippocampus, resulting in improved cognitive behavior in PS19 mice. The inhibitory effect of wtTIDM on tau pathology was absent in PS19 mice lacking TLR2, reinforcing the essential involvement of TLR2 in wtTIDM-mediated effects in vivo. Studying the mechanism further, we found that the tau promoter harbored a potential NF-κB-binding site and that proinflammatory molecules increased transcription of tau in neurons via NF-κB. These results suggest that tau-induced neuroinflammation and neuropathology require TLR2 and that neuroinflammation directly upregulates tau in neurons via NF-κB, highlighting a direct connection between inflammation and tauopathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci161987

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Tau PFFs induce microglial inflammation via TLR2. (A) Tau fibrils were prepared in vitro from full-length human tau monomers (2N4R isoform) and characterized by EM. Scale bar: 0.2 μm. (B–D) Induction of inflammatory molecules including iNOS, IL-1β, and TNF-α in WT primary microglia after treatment with different doses of tau PFFs (25, 50, and 100 nM) was measured by real-time PCR. Expression of iNOS (E), IL-1β (F), and TNF-α (G) in PFF-treated primary microglia derived from WT, TLR2–/–, and TLR4–/– pups was measured by real-time PCR. Protein expression of iNOS in PFF-induced primary microglia derived from WT (H and I), TLR2–/– (J and K), and TLR4–/– (L and M) pups was assessed by coimmunostaining of iNOS and Iba1, followed by MFI analysis of iNOS (green) using ImageJ. Scale bars: 20 μm. Statistical analyses among multiple groups were conducted using 1-way ANOVA followed by Tukey’s multiple-comparison analysis, whereas unpaired 2-tailed t test was conducted for comparing 2 groups. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the untreated control group. Values are presented as mean ± SD (n = 3 different experiments).
Figure 1 Tau PFFs induce microglial inflammation via TLR2. (A) Tau fibrils were prepared in vitro from full-length human tau monomers (2N4R isoform) and characterized by EM. Scale bar: 0.2 μm. (B–D) Induction of inflammatory molecules including iNOS, IL-1β, and TNF-α in WT primary microglia after treatment with different doses of tau PFFs (25, 50, and 100 nM) was measured by real-time PCR. Expression of iNOS (E), IL-1β (F), and TNF-α (G) in PFF-treated primary microglia derived from WT, TLR2–/–, and TLR4–/– pups was measured by real-time PCR. Protein expression of iNOS in PFF-induced primary microglia derived from WT (H and I), TLR2–/– (J and K), and TLR4–/– (L and M) pups was assessed by coimmunostaining of iNOS and Iba1, followed by MFI analysis of iNOS (green) using ImageJ. Scale bars: 20 μm. Statistical analyses among multiple groups were conducted using 1-way ANOVA followed by Tukey’s multiple-comparison analysis, whereas unpaired 2-tailed t test was conducted for comparing 2 groups. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the untreated control group. Values are presented as mean ± SD (n = 3 different experiments).CC BY · PubMed Central
Figure 2 The wtTIDM peptide inhibits tau PFF–induced TLR2-MyD88 interaction and NF-κB activation in microglia. (A) BV2 cells were pretreated with wtTIDM or mTIDM (10 μM), followed by exposure to PFFs (25 nM), and after 1 hour of PFF administration, the TLR2-MyD88 interaction was monitored by IP. Input samples were probed for both anti-TLR2 and anti-MyD88 antibodies. (B) Densitometry shows the MyD88-bound TLR2 level compared with the input. (C) The interaction of TLR4 with MyD88 was also assessed in BV2 cells by IP under identical experimental conditions. NF-κB activation was measured in nuclear extracts isolated from TIDM-treated, PFF-exposed BV2 cells by EMSA (D) and by luciferase assay, wherein cells were initially transfected with luciferase reporter gene constructs (E). (F and G) The level of activated NF-κB in TIDM-treated, PFF-exposed primary mouse microglia was assessed by immunostaining of the phospho-Ser536 form of p65 in Iba1+ microglia, followed by MFI analysis of phospho-p65. (H–J) Primary microglia were pretreated with wtTIDM or mTIDM (5 and 10 μM) and then challenged with tau PFFs for 5 hours, followed by expression analysis of inflammatory genes (iNOS, IL-1β, and TNF-α) by real-time PCR. (K) The level of iNOS protein expression in TIDM-treated primary microglia was analyzed after 16 hours of PFF exposure by immunostaining. Scale bars: 20 μm. (L) MFI of iNOS expression was measured by ImageJ. Statistical analyses were performed by 1-way ANOVA, followed by Tukey’s multiple-comparison analysis. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the designated groups. Values are presented as mean ± SD (n = 3 different experiments).
Figure 2 The wtTIDM peptide inhibits tau PFF–induced TLR2-MyD88 interaction and NF-κB activation in microglia. (A) BV2 cells were pretreated with wtTIDM or mTIDM (10 μM), followed by exposure to PFFs (25 nM), and after 1 hour of PFF administration, the TLR2-MyD88 interaction was monitored by IP. Input samples were probed for both anti-TLR2 and anti-MyD88 antibodies. (B) Densitometry shows the MyD88-bound TLR2 level compared with the input. (C) The interaction of TLR4 with MyD88 was also assessed in BV2 cells by IP under identical experimental conditions. NF-κB activation was measured in nuclear extracts isolated from TIDM-treated, PFF-exposed BV2 cells by EMSA (D) and by luciferase assay, wherein cells were initially transfected with luciferase reporter gene constructs (E). (F and G) The level of activated NF-κB in TIDM-treated, PFF-exposed primary mouse microglia was assessed by immunostaining of the phospho-Ser536 form of p65 in Iba1+ microglia, followed by MFI analysis of phospho-p65. (H–J) Primary microglia were pretreated with wtTIDM or mTIDM (5 and 10 μM) and then challenged with tau PFFs for 5 hours, followed by expression analysis of inflammatory genes (iNOS, IL-1β, and TNF-α) by real-time PCR. (K) The level of iNOS protein expression in TIDM-treated primary microglia was analyzed after 16 hours of PFF exposure by immunostaining. Scale bars: 20 μm. (L) MFI of iNOS expression was measured by ImageJ. Statistical analyses were performed by 1-way ANOVA, followed by Tukey’s multiple-comparison analysis. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the designated groups. Values are presented as mean ± SD (n = 3 different experiments).CC BY · PubMed Central
Figure 3 The wtTIDM nasal administration suppresses gliosis and inflammation in the hippocampus of PS19 animals. (A) PS19 mice (7 months old) were given intranasal administration of wtTIDM or mTIDM (0.1 mg/kg) for 1.5 months, and then activation of NF-κB in resident microglia of hippocampus was monitored by double-label immunofluorescence analysis of phospho-p65 in Iba1+ cells. (B) Images were captured at 20× magnification and zoomed to visualize phospho-p65 localization. Expression of phospho-p65 (green) was measured by MFI analysis. (C) Similarly, expression of iNOS in hippocampal microglia was monitored by double immunofluorescence analysis of iNOS and Iba1. Images were captured at 20× magnification. Scale bars: 20 μm. (D) iNOS expression (green) in Iba1+ cells was measured using ImageJ. (E) The number of Iba1+ cells in both the CA1 and DG regions was determined by the manual counting option provided in ImageJ and expressed as cells per mm2 of area. (F) For both MFI and counting analyses, microglia present in both CA1 and DG were considered. Two sections from each brain were included for immunofluorescence analysis, and the value obtained from each section is represented in the bar diagram. The protein level of iNOS as well as Iba1 in hippocampal tissue was also measured by Western blotting, and actin was used the loading control. (G and H) Band densities of iNOS and Iba1 were presented with respect to that of actin. Statistical analyses were performed following 1-way ANOVA followed by Tukey’s multiple-comparison analysis. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the designated groups. Values are presented as mean ± SEM (n = 5 different animals).
Figure 3 The wtTIDM nasal administration suppresses gliosis and inflammation in the hippocampus of PS19 animals. (A) PS19 mice (7 months old) were given intranasal administration of wtTIDM or mTIDM (0.1 mg/kg) for 1.5 months, and then activation of NF-κB in resident microglia of hippocampus was monitored by double-label immunofluorescence analysis of phospho-p65 in Iba1+ cells. (B) Images were captured at 20× magnification and zoomed to visualize phospho-p65 localization. Expression of phospho-p65 (green) was measured by MFI analysis. (C) Similarly, expression of iNOS in hippocampal microglia was monitored by double immunofluorescence analysis of iNOS and Iba1. Images were captured at 20× magnification. Scale bars: 20 μm. (D) iNOS expression (green) in Iba1+ cells was measured using ImageJ. (E) The number of Iba1+ cells in both the CA1 and DG regions was determined by the manual counting option provided in ImageJ and expressed as cells per mm2 of area. (F) For both MFI and counting analyses, microglia present in both CA1 and DG were considered. Two sections from each brain were included for immunofluorescence analysis, and the value obtained from each section is represented in the bar diagram. The protein level of iNOS as well as Iba1 in hippocampal tissue was also measured by Western blotting, and actin was used the loading control. (G and H) Band densities of iNOS and Iba1 were presented with respect to that of actin. Statistical analyses were performed following 1-way ANOVA followed by Tukey’s multiple-comparison analysis. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the designated groups. Values are presented as mean ± SEM (n = 5 different animals).CC BY · PubMed Central
Figure 4 wtTIDM nasal administration alleviates aggregated tau deposition in the hippocampus of PS19 animals. PS19 mice (7 months old) were given intranasal administration of wtTIDM or mTIDM (0.1 mg/kg) for 1.5 months, and content of NFTs in hippocampal neurons was assessed by immunohistochemistry using antibody specific for total tau (Tau-5). Images obtained from the DG (A) and CA1 (C) brain regions of the experimental PS19 mice are shown at 20× and 40× magnifications. Scale bars: 20 μm (left columns), 10 μm (right columns). (B and D) Relative OD of Tau-5 staining compared with the nTg mice was measured using Fiji. Two sections from each brain were included for immunostaining analysis, and the value obtained from each section is represented in the bar diagram. The total level of tau present in sarkosyl-soluble (sol) (E) and sarkosyl-insoluble (Insol) (G) tissue fractions was assessed by Western blotting. (F) The expression of total tau in the sarkosyl-soluble fraction was represented with respect to the actin present in the sarkosyl-soluble fraction. (H) On the other hand, the level of total tau in the sarkosyl-insoluble fraction was represented with respect to the actin present in the sarkosyl-soluble fraction, as an actin band was not found in the sarkosyl-insoluble fraction. Arrows indicate the different isomers of tau, and the band near 70 kDa obtained from the sarkosyl-soluble fraction was considered for density analysis. Statistical analyses were conducted following 1-way ANOVA followed by Tukey’s multiple-comparison analysis. ***P < 0.001 compared with the respective groups. Values are presented as mean ± SEM (n = 5 different animals).
Figure 4 wtTIDM nasal administration alleviates aggregated tau deposition in the hippocampus of PS19 animals. PS19 mice (7 months old) were given intranasal administration of wtTIDM or mTIDM (0.1 mg/kg) for 1.5 months, and content of NFTs in hippocampal neurons was assessed by immunohistochemistry using antibody specific for total tau (Tau-5). Images obtained from the DG (A) and CA1 (C) brain regions of the experimental PS19 mice are shown at 20× and 40× magnifications. Scale bars: 20 μm (left columns), 10 μm (right columns). (B and D) Relative OD of Tau-5 staining compared with the nTg mice was measured using Fiji. Two sections from each brain were included for immunostaining analysis, and the value obtained from each section is represented in the bar diagram. The total level of tau present in sarkosyl-soluble (sol) (E) and sarkosyl-insoluble (Insol) (G) tissue fractions was assessed by Western blotting. (F) The expression of total tau in the sarkosyl-soluble fraction was represented with respect to the actin present in the sarkosyl-soluble fraction. (H) On the other hand, the level of total tau in the sarkosyl-insoluble fraction was represented with respect to the actin present in the sarkosyl-soluble fraction, as an actin band was not found in the sarkosyl-insoluble fraction. Arrows indicate the different isomers of tau, and the band near 70 kDa obtained from the sarkosyl-soluble fraction was considered for density analysis. Statistical analyses were conducted following 1-way ANOVA followed by Tukey’s multiple-comparison analysis. ***P < 0.001 compared with the respective groups. Values are presented as mean ± SEM (n = 5 different animals).CC BY · PubMed Central
Figure 5 Hippocampal synaptic plasticity is retained by nasal wtTIDM treatment in PS19 mouse brains. (A) PS19 mice (7 months old) were given intranasal administration of wtTIDM or mTIDM (0.1 mg/kg) for 1.5 months. Hippocampal plasticity was primarily monitored by evaluating the level of PSD95 in pyramidal neurons of CA1 by double immunofluorescence of PSD95 and MAP2. Scale bar: 10 μm. (B) Expression of PSD95 (green) surrounding each DAPI+ nucleus in the pyramidal layer was measured by drawing the region of interest, then using the analyze-measure tool of ImageJ. The MFI data obtained from each section of a particular mouse brain are shown in the bar diagram. (C and D) Similarly, overall protein content of PSD95 in the hippocampus was assessed by Western blot analysis. *P < 0.05 and **P < 0.01 compared with the corresponding groups. Values are presented as mean ± SEM (n = 5 different animals). (E) NMDA-dependent Ca influx in hippocampal slices from experimental animals was measured by treating the slices with NMDA and NASPM (for blocking AMPA-mediated Ca influx). (F) Similarly, AMPA-dependent Ca influx was measured by using AMPA along with N20C (NMDA open-channel blocker). Fluorescence based Ca influx was monitored for 300 repeats in a PerkinElmer VICTOR X2 fluorimeter. The experiment was conducted on samples from 3 different mouse brains of each group.
Figure 5 Hippocampal synaptic plasticity is retained by nasal wtTIDM treatment in PS19 mouse brains. (A) PS19 mice (7 months old) were given intranasal administration of wtTIDM or mTIDM (0.1 mg/kg) for 1.5 months. Hippocampal plasticity was primarily monitored by evaluating the level of PSD95 in pyramidal neurons of CA1 by double immunofluorescence of PSD95 and MAP2. Scale bar: 10 μm. (B) Expression of PSD95 (green) surrounding each DAPI+ nucleus in the pyramidal layer was measured by drawing the region of interest, then using the analyze-measure tool of ImageJ. The MFI data obtained from each section of a particular mouse brain are shown in the bar diagram. (C and D) Similarly, overall protein content of PSD95 in the hippocampus was assessed by Western blot analysis. *P < 0.05 and **P < 0.01 compared with the corresponding groups. Values are presented as mean ± SEM (n = 5 different animals). (E) NMDA-dependent Ca influx in hippocampal slices from experimental animals was measured by treating the slices with NMDA and NASPM (for blocking AMPA-mediated Ca influx). (F) Similarly, AMPA-dependent Ca influx was measured by using AMPA along with N20C (NMDA open-channel blocker). Fluorescence based Ca influx was monitored for 300 repeats in a PerkinElmer VICTOR X2 fluorimeter. The experiment was conducted on samples from 3 different mouse brains of each group.CC BY · PubMed Central
Figure 6 Cognition is improved in PS19 animals by wtTIDM administration. (A) PS19 mice (7 months old) were given intranasal administration of wtTIDM or mTIDM (0.1 mg/kg) for 1 month, and then spatial memory of these animals was evaluated by conducting Barnes maze analysis; the heatmaps demonstrate the exploratory activity of the animals in the maze to find out the goal box (n = 7 animals per group). Cognitive parameters including total errors made before reaching the goal box (B) and latency time for the reaching goal box (C) are shown in the diagrams. (D) NORT was conducted to explore the memory-retention ability of the experimental mice. Time spent by each mouse with the familiar object (E) and with the novel object.\ (F) was recorded for determining the cognitive performance of different groups of mice (n = 6 animals per group). Locomotor activity of mice was assessed by performing an open-field test (G), in which parameters including distance (H), velocity (I), and center frequency (J) in the arena were recorded. (K) Motor coordination was evaluated by rotarod test (n = 7 animals per group). Statistical analyses were performed with 1-way ANOVA followed by Tukey’s multiple-comparison analysis. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the designated groups. Values are presented as mean ± SEM.
Figure 6 Cognition is improved in PS19 animals by wtTIDM administration. (A) PS19 mice (7 months old) were given intranasal administration of wtTIDM or mTIDM (0.1 mg/kg) for 1 month, and then spatial memory of these animals was evaluated by conducting Barnes maze analysis; the heatmaps demonstrate the exploratory activity of the animals in the maze to find out the goal box (n = 7 animals per group). Cognitive parameters including total errors made before reaching the goal box (B) and latency time for the reaching goal box (C) are shown in the diagrams. (D) NORT was conducted to explore the memory-retention ability of the experimental mice. Time spent by each mouse with the familiar object (E) and with the novel object.\ (F) was recorded for determining the cognitive performance of different groups of mice (n = 6 animals per group). Locomotor activity of mice was assessed by performing an open-field test (G), in which parameters including distance (H), velocity (I), and center frequency (J) in the arena were recorded. (K) Motor coordination was evaluated by rotarod test (n = 7 animals per group). Statistical analyses were performed with 1-way ANOVA followed by Tukey’s multiple-comparison analysis. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the designated groups. Values are presented as mean ± SEM.CC BY · PubMed Central
Figure 7 The wtTIDM treatment fails to reduce tau pathology and improve cognitive behavior in PS19 mice lacking TLR2. (A) PS19 mice were bred with TLR2–/– mice to obtain double-transgenic PS19ΔTLR2 mice. These mice were validated by genetic screening, where the 331 bp and 279 bp bands corresponded to nTg and PS19 mice, respectively. Similarly, the 499 bp and 334 bp bands indicate nTg and TLR2–/– mice respectively. PS19ΔTLR2 mice (7 months old) received wtTIDM (0.1 mg/kg/d) nasal administration for 1 month; and at 8.5 months of age, tau pathology in the hippocampus was compared with that of untreated PS19ΔTLR2 and PS19 mice by conducting immunohistochemistry with Tau-5 antibodies. Tau aggregation was monitored in both DG (B) and CA1 (D) neurons. Scale bars: 20 μm (left columns), 10 μm (right columns). (C and E) OD of tau expression was calculated relative to that in nTg mice. Two sections from each brain were used for the staining and quantitative analysis of tau expression, and the values obtained from each section are shown in the bar diagram. Images are shown at 20× and 40× magnifications. Total tau content in sarkosyl-soluble (F) and insoluble fractions (H) was assessed by Western blotting. The tau band densities obtained from the sarkosyl-soluble (G) and -insoluble fractions (I) was normalized to the loading control, actin, present in the soluble fraction. Arrows indicate the different isomers of tau, and the band near 70 kDa obtained from the sarkosyl-soluble fraction was considered for density analysis. Spatial learning and memory were tested by Barnes maze (J, heat map; K, error; L, latency). Statistical analyses were performed using 2-way ANOVA followed by Tukey’s multiple-comparison analysis. **P < 0.01 and ***P < 0.001 compared with the respective groups. Values are presented as mean ± SEM (n = 4 animals per group).
Figure 7 The wtTIDM treatment fails to reduce tau pathology and improve cognitive behavior in PS19 mice lacking TLR2. (A) PS19 mice were bred with TLR2–/– mice to obtain double-transgenic PS19ΔTLR2 mice. These mice were validated by genetic screening, where the 331 bp and 279 bp bands corresponded to nTg and PS19 mice, respectively. Similarly, the 499 bp and 334 bp bands indicate nTg and TLR2–/– mice respectively. PS19ΔTLR2 mice (7 months old) received wtTIDM (0.1 mg/kg/d) nasal administration for 1 month; and at 8.5 months of age, tau pathology in the hippocampus was compared with that of untreated PS19ΔTLR2 and PS19 mice by conducting immunohistochemistry with Tau-5 antibodies. Tau aggregation was monitored in both DG (B) and CA1 (D) neurons. Scale bars: 20 μm (left columns), 10 μm (right columns). (C and E) OD of tau expression was calculated relative to that in nTg mice. Two sections from each brain were used for the staining and quantitative analysis of tau expression, and the values obtained from each section are shown in the bar diagram. Images are shown at 20× and 40× magnifications. Total tau content in sarkosyl-soluble (F) and insoluble fractions (H) was assessed by Western blotting. The tau band densities obtained from the sarkosyl-soluble (G) and -insoluble fractions (I) was normalized to the loading control, actin, present in the soluble fraction. Arrows indicate the different isomers of tau, and the band near 70 kDa obtained from the sarkosyl-soluble fraction was considered for density analysis. Spatial learning and memory were tested by Barnes maze (J, heat map; K, error; L, latency). Statistical analyses were performed using 2-way ANOVA followed by Tukey’s multiple-comparison analysis. **P < 0.01 and ***P < 0.001 compared with the respective groups. Values are presented as mean ± SEM (n = 4 animals per group).CC BY · PubMed Central
Figure 8 Inflammation induces neuronal tau expression via NF-κB activation. (A) Human SH-SY5Y cells were stimulated with different concentrations of IL-1β under serum-free conditions for 18 hours, then the level of total tau was monitored by Western blotting using Tau-5 antibody. Actin was run as a loading control. (B and C) Tau bands were scanned, and values (B, variant 1/actin; C, variant 2/actin) presented as relative (Rel.) to control. (D) Cells were double-labeled with Tau-5 and NeuN. (E) MFI of tau was measured by NIH ImageJ in 3 images of each of 3 different experiments. (F) After different periods of stimulation with IL-1β, the DNA-binding activity of NF-κB was monitored in nuclear extracts by EMSA. (G) Cells were transfected with PBIIx-Luc for 24 hours, followed by treatment with different concentrations of IL-1β for 4 hours, then luciferase assay in total cell extracts. (H) Map of the WT and mutated NF-κB sites of MAPT promoter luciferase constructs. (I) Cells were transfected with pMAPT(WT)-Luc and pMAPT(mut)-Luc for 24 hours, followed by treatment with IL-1β, and subjected to luciferase assay after 4 hours of stimulation. Cells were treated with IL-1β for 1 hour in serum-free medium, followed by ChIP analysis. Immunoprecipitated chromatin fragments were amplified by semiquantitative (J) and quantitative PCR (K) using primers mentioned in Methods. (L) Cells preincubated with either wtNBD peptide or mNBD peptide for 30 minutes were stimulated by IL-1β for 4 hours, followed by analysis of MAPT mRNAs by quantitative real-time PCR. (M) The schematic diagram showing a detailed map of promoter analysis of the MAPT gene. Results are the mean ± SD of 3 separate experiments. One-way ANOVA followed by Tukey’s multiple-comparison test was used for statistical analyses. *P < 0.05 and ***P < 0.001 versus control.
Figure 8 Inflammation induces neuronal tau expression via NF-κB activation. (A) Human SH-SY5Y cells were stimulated with different concentrations of IL-1β under serum-free conditions for 18 hours, then the level of total tau was monitored by Western blotting using Tau-5 antibody. Actin was run as a loading control. (B and C) Tau bands were scanned, and values (B, variant 1/actin; C, variant 2/actin) presented as relative (Rel.) to control. (D) Cells were double-labeled with Tau-5 and NeuN. (E) MFI of tau was measured by NIH ImageJ in 3 images of each of 3 different experiments. (F) After different periods of stimulation with IL-1β, the DNA-binding activity of NF-κB was monitored in nuclear extracts by EMSA. (G) Cells were transfected with PBIIx-Luc for 24 hours, followed by treatment with different concentrations of IL-1β for 4 hours, then luciferase assay in total cell extracts. (H) Map of the WT and mutated NF-κB sites of MAPT promoter luciferase constructs. (I) Cells were transfected with pMAPT(WT)-Luc and pMAPT(mut)-Luc for 24 hours, followed by treatment with IL-1β, and subjected to luciferase assay after 4 hours of stimulation. Cells were treated with IL-1β for 1 hour in serum-free medium, followed by ChIP analysis. Immunoprecipitated chromatin fragments were amplified by semiquantitative (J) and quantitative PCR (K) using primers mentioned in Methods. (L) Cells preincubated with either wtNBD peptide or mNBD peptide for 30 minutes were stimulated by IL-1β for 4 hours, followed by analysis of MAPT mRNAs by quantitative real-time PCR. (M) The schematic diagram showing a detailed map of promoter analysis of the MAPT gene. Results are the mean ± SD of 3 separate experiments. One-way ANOVA followed by Tukey’s multiple-comparison test was used for statistical analyses. *P < 0.05 and ***P < 0.001 versus control.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 87

Metadata

Authors
Dutta, D., Jana, M., Paidi, R. K., Majumder, M., Raha, S., Dasarathy, S., & Pahan, K.
Affiliations
Rush University Medical Center (US)
Corresponding author
Pahan, Kalipada
Venue
Journal of Clinical Investigation
Published
2023-09-15
Volume
133
Issue
18
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4385667068
Cited by
87
References
68
Citations by year
2026: 26 · 2025: 37 · 2024: 21 · 2023: 3
FWCI
15.45
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Veterans Affairs (AG069229, 1IK6 BX004982, IK6 BX004982, AG050431)
  • University of Pennsylvania
  • National Institutes of Health (1IK6 BX004982, AG069229, AG050431)
  • National Institute on Aging (R21AG069229, R01AG050431)
  • National Center for Complementary and Integrative Health (R01AT010980)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Keywords
tau fibrils, neuroinflammation, TLR2, MyD88, NF-κB signaling, microglial activation, glial activation, tauopathy, Alzheimer's disease, NF-kappaB binding site, gliosis, P301S tau, PS19 mice, cognitive behavior, hippocampus
MeSH terms
Neuroinflammatory Diseases, Alzheimer Disease, Animals, Disease Models, Animal, Inflammation, Mice, Transgenic, NF-kappa B, tau Proteins, Microglia, Adaptor Proteins, Signal Transducing, Toll-Like Receptor 2, Mice, Myeloid Differentiation Factor 88

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tau fibrils induce glial inflammation and neuropathology via TLR2 in Alzheimer’s disease–related mouse models. https://app.cochat.ai/papers/10.1172/jci161987
The paper
Dutta, D., Jana, M., Paidi, R. K., Majumder, M., Raha, S., Dasarathy, S., & Pahan, K. (2023). Tau fibrils induce glial inflammation and neuropathology via TLR2 in Alzheimer’s disease–related mouse models. Journal of Clinical Investigation. https://doi.org/10.1172/jci161987

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.